more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research Published on June 29,2020

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.

medical

Why Is Conmed (CNMD) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research Published on May 29,2020

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNMDNegative Net Change

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research Published on May 28,2020

CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.

medical

CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research Published on May 04,2020

CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

Conmed (CNMD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research Published on April 29,2020

Conmed (CNMD) delivered earnings and revenue surprises of 15.91% and 2.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CNMDNegative Net Change

Earnings Preview: Conmed (CNMD) Q1 Earnings Expected to Decline

by Zacks Equity Research Published on April 22,2020

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNMDNegative Net Change

MMSI vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on April 09,2020

MMSI vs. CNMD: Which Stock Is the Better Value Option?

Want To Retire Early? Learn the Intelligent Investing Secret - March 24, 2020

by Zacks Equity Research Published on March 24,2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research Published on March 12,2020

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.

medical

Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show

by Sreyoshi Mukherjee Published on March 12,2020

The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.

medical

Why Is Conmed (CNMD) Down 6.5% Since Last Earnings Report?

by Zacks Equity Research Published on February 28,2020

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNMDNegative Net Change

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on February 25,2020

XRAY vs. CNMD: Which Stock Is the Better Value Option?

XRAY or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on February 05,2020

XRAY vs. CNMD: Which Stock Is the Better Value Option?

CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research Published on January 31,2020

CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.

medical

Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research Published on January 29,2020

Conmed (CNMD) delivered earnings and revenue surprises of 1.12% and 0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CNMDNegative Net Change

Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More

by Urmimala Biswas Published on January 28,2020

A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.

Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on January 22,2020

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.